Korro Bio presents KRRO-121 trial plans, targets interim data in second half of 2027
KRRO•Korro Bio expects to begin dosing urea cycle disorder patients with KRRO-121 in the first half of 2027, with interim Phase 1/2 trial data expected in the second half of 2027. The company also plans a KRRO-111 regulatory submission in the first half of 2027 and expects cash to last into the second half of 2028.
1. Pipeline timelines
Korro Bio expects to begin dosing urea cycle disorder patients with KRRO-121 in the first half of 2027 and anticipates interim data from its ongoing Phase 1/2 trial in the second half of that year. A regulatory submission for KRRO-111, which targets alpha-1 antitrypsin deficiency, is planned for the first half of 2027.
2. Other milestones and cash
The company expects to select a development candidate for a third GalNAc-conjugated liver asset in the second half of 2026. Its cash runway extends into the second half of 2028.
